Life Science Investor Mandates
(Oct. 11 - Oct. 17
)
|
|
|
|
|
Invests Up to $5M in Early-Stage Life Science Technologies in North America
|
|
Seeking Investment Opportunities in Cell/Gene Therapy, Cell Engineering, and Life Sciences Tools
|
|
Invests in First-In-Class, Early-Stage Assets in Areas of Unmet Medical Need
|
|
Invests in Life Science Technologies Addressing Orphan & Rare Diseases, with Strong Interest in Novel Therapeutics
|
|
|
 RESI NYC is just over 2 weeks away, on Monday, November 5th, and we are happy to announce the thirty finalists for the RESI Innovation Challenge. The Innovation Challenge finalists span from therapeutics to medical devices to diagnostics and digital health. The Innovation Challenge is designed to allow the finalists a chance to showcase their technology to the investors and strategic partners attending RESI, beyond the one-on-one Partnering Forum - make sure to stop by and look at their innovative technologies! Each attendee will receive "RESI Cash" to "invest" in their favorite company (or companies). The top three companies will receive prizes at the end of the day, so make sure to go through the exhibit hall and check out all of the IC Finalist posters...
|
 |
 It's only October, but the annual San Francisco healthcare week in January feels just around the corner. On Tuesday January 8th, RESI will return to the Union Square fray with a 1-day event packed with one-on-one meetings, networking and content for life science entrepreneurs. Last year, this event attracted over 500 early stage investors - and we've often heard from attendees that if you're headed to JPM, there's no better place than RESI for venture-stage companies to look for financing...
|
 |
|
|
 Our next conference, RESI NYC, is now less than 3 weeks away and it is a pleasure to announce the Health System Partners panel. This has become one of our more frequently featured - and certainly interesting - discussion topics, as an increasing amount of health systems and large hospital organizations are becoming actively involved in fostering innovation that can benefit the course of healthcare. One important consideration is that each firm has a unique approach in partnering with early-stage companies. From traditional VC-like firms to hands-on accelerator programs, there is something for everyone.
There is no doubt that these groups provide a tremendous value add, but how can entrepreneurs properly engage with them? What kind of expectations do they have when evaluating startup opportunities? To whom should entrepreneurs reach out, and what is the investment process like for each organization? These are the types of questions that will be addressed on the Health System Partners panel at RESI NYC, on Monday, November 5th, 2018.
|
 |
|
|
Created & Produced by
|
 |
|
|
|
